ABOUT THIS STUDY
1. Males or females who weigh at least 9 kg
2. Anticipated to be living or working in the same household (> or = 10 hours per week and expected to have direct contact with the participant) as a participant in the Phase 3 interventional study, C3391003, for at least 4 months from the time of the screening visit. The participant in C3391003 must have completed their Baseline Visit, but not yet have received IP as part of C3391003
3. The C3391003 participant is subsequently dosed with study intervention after the Baseline Visit
1. Prior treatment with gene therapy utilizing AAV vectors of any serotype.
2. Living or working in a household where 5 other participants are already participating
in this study (C3391007).
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.